Last reviewed · How we verify
Cabozantinib tablets
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and AXL signaling to inhibit tumor growth and angiogenesis.
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and AXL signaling to inhibit tumor growth and angiogenesis. Used for Metastatic renal cell carcinoma, Hepatocellular carcinoma, Medullary thyroid cancer.
At a glance
| Generic name | Cabozantinib tablets |
|---|---|
| Also known as | XL184 |
| Sponsor | Exelixis |
| Drug class | Multi-targeted tyrosine kinase inhibitor |
| Target | MET, VEGFR2, AXL |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cabozantinib inhibits multiple receptor tyrosine kinases including MET (hepatocyte growth factor receptor), VEGFR2 (vascular endothelial growth factor receptor 2), and AXL, which are involved in tumor cell proliferation, survival, and angiogenesis. By blocking these pathways, the drug suppresses tumor growth and reduces the formation of new blood vessels that feed tumors. This multi-targeted approach is particularly effective in cancers with MET or VEGFR2 dependency.
Approved indications
- Metastatic renal cell carcinoma
- Hepatocellular carcinoma
- Medullary thyroid cancer
- Castration-resistant prostate cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Decreased appetite
- Vomiting
- Hypertension
- Palmar-plantar erythrodysesthesia
- Abdominal pain
Key clinical trials
- A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (PHASE3)
- Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (PHASE2)
- Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas (PHASE1)
- Cabozantinib for Patients With Recurrent or Progressive Meningioma (PHASE2)
- A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) (PHASE3)
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases (PHASE2)
- A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
- Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |